Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Protalix BioTherapeutics, Inc.
Type
Public
Traded as NYSE MKT: PLX
TASE: PLX
Industry Biotechnology
Founded 1993 (1993)
Founder Yoseph Shaaltiel
Headquarters Carmiel, Israel
Key people
Zeev Bronfeld (Interim Chairman)
David Aviezer (President and CEO)
Products Elelyso
Revenue Decrease $11.51 million (2013)
Total assets Increase $113.33 million (2013)
Number of employees
266 (2013)
Website www.protalix.com
Footnotes / references

Protalix BioTherapeutics is an Israeli pharmaceutical company whose plant-based enzyme, taliglucerase alfa, has been approved by the U.S. Food and Drug Administration for the treatment of Gaucher disease.

Investment goal date:
Dividends reinvested
Protalix BioTherapeutics, Inc. PLX report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-13
--
--
Q3 2017
2017-11-09
--
--
Q2 2017
2017-08-09
-0.0700
-0.0600
Q1 2017
2017-05-10
-0.0500
-0.4800
Q4 2016
2017-03-16
-0.1300
-0.0200
Q3 2016
2016-11-09
-0.0700
-0.0700
Q2 2016
2016-08-08
-0.1100
-0.1100
Q1 2016
2016-05-09
-0.0900
-0.0900
Q4 2015
2016-03-08
0.7700
-0.0800
Q3 2015
2015-11-10
-0.0400
-0.0600
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks